Other small molecular compounds whose mechanisms of action have been quite well-characterized are omecamtiv mecarbil (OM) [18,19,20,21,22,23,24,25], initially introduced as a myosin activator in heart failure [26,27], and the blebbistatin family of myosin-inhibiting compounds [6,28,29,30,31,32,33,34,35]. The gene discussed is MYH14; the disease is ocular melanoma.